VivoSim Labs Inc VIVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.19
- Day Range
- $1.15–1.21
- 52-Week Range
- $1.13–5.30
- Bid/Ask
- $1.18 / $1.19
- Shares Outstanding
- 2.89M
- Market Cap
- $3.42M
- Volume/Avg
- 15,765 / 69,938
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.organovo.com
Valuation
|
Metric
|
VIVS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.69 |
Price/Sales | 19.25 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VIVS
|
|---|---|
Quick Ratio | 2.15 |
Current Ratio | 2.44 |
Interest Coverage | −111.85 |
Quick Ratio
VIVS
Profitability
|
Metric
|
VIVS
|
|---|---|
Return on Assets (Normalized) | −94.27% |
Return on Equity (Normalized) | −139.24% |
Return on Invested Capital (Normalized) | −125.89% |
Return on Assets
VIVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Rplmmjsjk | Rhtcy | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Grtkwhk | Xfkbsw | $65B | |||
| argenx SE ADR
ARGX
| Mfjgndfvf | Qxk | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Skjlgxhhk | Kdmbs | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Nlbnlyfsqx | Zrpwrlb | $25B | |||
| BioNTech SE ADR
BNTX
| Cnrnkjzjj | Mkc | $22B | |||
| Incyte Corp
INCY
| Fqldqhdns | Nlykv | $21B | |||
| Moderna Inc
MRNA
| Tnsnhxtj | Sfm | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Zqspgnmj | Cnjqk | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Lhtfxdzw | Ygdtd | $13B |
United States